Herceptin: Long-Term Benefits for Breast Cancer, San Raffaele University Study

WebMD -- Feb. 24, 2011 -- High-risk breast cancer patients continue to derive benefits from the drug Herceptin even four years after stopping treatment, but questions remain about the biologic therapy’s safety when given with chemotherapy. Newly reported follow-up data from a large international study show that women with early-stage HER2-positive breast tumors who took Herceptin for one year are 24% less likely to have their tumors return after four years than women who did not take the drug.